Portfolio company
KyDo
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This biotechnology company develops small molecule inhibitors for the treatment of cancer variants in oncology patients.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
KyDo Therapeutics
This company develops covalent-allosteric small molecule inhibitors for the treatment of challenging cancer variants within the oncology sector.
HYKU Biosciences
This biotechnology company develops precision covalent small-molecule medicines targeting disease-driving proteins to treat patients with cancer and other illnesses.
Kinnate Biopharma
The company develops small molecule kinase inhibitors for patients with difficult-to-treat cancers featuring specific genetic alterations.
tolremo
This company develops small molecule drugs to prevent non-genetic resistance in cancer patients receiving targeted therapies.
Kymera Therapeutics
This biotechnology company develops small molecule medicines that degrade disease-causing proteins for patients with cancer and immune-inflammatory diseases.
Flindr Therapeutics
This company develops small molecule inhibitors for the precision treatment of cancer patients with specific tumor and host factors.
Flindr
The company develops small molecule inhibitors for precision oncology treatments to improve outcomes for cancer patients.
1200 Pharma
This biotechnology firm develops small molecule therapies and drug intellectual property for the treatment of cancer patients.